May 14, 2026
TempraMed Technologies Ltd.
ISIN: CA88024B1022
TempraMed Announces Granted Indian Design Patent for VIVI Cap Smart Product
Another major milestone in its continuous global IP strategy, advancing protection of VIVI Cap Smart across international markets Highlights - Granted Patent covers the design of VIVI Cap Smart across major international,...
Read more >>TempraMed Partners with Super-Pharm, Israel’s Leading Pharmacy Chain to Commence a National Product Roll Out Strategy
Super-Pharm operates nationwide, serving millions of consumers annually Vancouver, BC - February 10, 2026 - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce the rollout of its products across Super‑Pharm, Israel’s largest and...
Read more >TempraMed Launches National Brick and Mortar Pharmacy Roll Out, Shipping Products to Maccabi Pharmacies Across Israel
Key Commercialization Milestone in Retail Pharmacy Network that Serves Over 2.8 Million Insured Members Vancouver, BC – February 6, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has completed...
Read more >TempraMed Enters Strategic Media Partnership with Dr. Phil’s Envoy Media, Validating Product Portfolio and Accelerating Market Adoption Across the United States
Access to an audience of over 19 million individuals monthly will expand national exposure, and supports scalable demand generation across B2C and B2B channels for TempraMed’s full product portfolio Vancouver, BC – February 2, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator...
Read more >TempraMed Launches New Product “VIVI Med™, Unlocking New Growth Opportunities in High-Value Biologics and Injectable Medications
Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional channels Highlights - Uses same fully patented, thermal-protection technology across product portfolio with four products in market that keep room temperature medications at optimal temperature- Designed for medications...
Read more >TempraMed Receives Positive Response on Payor Reimbursement Model Driving Significant Return on Investment for Medical Payor Coverage
Validation is expected to accelerate TempraMed’s path to payor reimbursement for product portfolio Highlights - ROI model validated for savings and metrics by Validation Institute, a leading authority in healthcare value and economic credibility- Confirms that payors covering VIVI Cap™ can achieve meaningful cost savings and return on investment- Supports TempraMed’s planned...
Read more >TempraMed Closes C$2.5 Million Fully Subscribed Private Placement
Vancouver, BC – January 12, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce the fully subscribed closing of its previously announced non-brokered private placement (the "Offering"), issuing 3,322,153 units (each,...
Read more >TempraMed Receives First Commercial Order from Israel Distributor and Completes Initial Shipment Enabling Entry into National Pharmacy Network
Initial shipment delivered to distributor warehouse supports expansion into B2B pharmacy distribution alongside direct-to-consumer activities Vancouver, BC - January 7, 2026 - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce its first commercial...
Read more >TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026
Vancouver, BC – January 2, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide a positive recap on the year as well as a strategic outlook for the year ahead...
Read more >TempraMed Deepens Asian Market Penetration with Expanded Distribution Partnership and Meaningful Commercial Order in South Korea
Expansion builds on newly granted South Korean patent, rising local demand and following the launch of digitally connected “VIVI Cap Smart” device Vancouver, BC – December 31, 2025 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed,...
Read more >TempraMed Launches New Product, VIVI Cap Smart, Expanding its Portfolio to Include a Digital Health Offering
Integrated smart technology builds on TempraMed’s proven VIVI platform, providing robust Temperature control with medication management for individuals using life-saving medication Highlights: Expands TempraMed’s product portfolio and adds a digital component to track and record medication use. First in the world platform that turns almost every insulin and GLP-1 pens to...
Read more >TempraMed Expands U.S. Manufacturing Capacity with New Production Facility in Florida
New facility increases output, reduces cost of goods sold (COGS) and enhances service for B2B customers to address the forecasted increased demand for products Highlights: - Manufacturing site in Florida expands TempraMed’s U.S. production footprint- Increases capacity to meet rising demand from healthcare organizations, pharmacies, payors, and device manufacturers- Shortens delivery...
Read more >TempraMed Strengthens Global Intellectual Property Position with Grant of South Korean Patent
Highlights - Newly granted patent protects TempraMed’s VIVI Box™ proprietary, hassle-free thermal-insulation system and smart-monitoring architecture- Expands the Company’s ability to adapt its core technology to a wider range of drug categories-from chronic self-injectables to complex biologics- Enhances commercialization opportunities and supports strategic engagement with leading appliance manufacturers in Asia’s premium...
Read more >